Add-on parsaclisib (a PI3K5 inhibitor) in patients with myelofibrosis and suboptimal response to ruxolitinib: Interim analysis from a phase 2 study Meeting Abstract
| Authors: | Yacoub, A.; Borate, U.; Rampal, R.; Ali, H.; Wang, E.; Gerds, A.; Hobbs, G.; Kremyanskaya, M.; Winton, E.; O'Connell, C.; Goel, S.; Oh, S.; Schiller, G.; Assad, A.; Erickson-Viitanen, S.; Chen, X. J.; Zhou, F.; Daver, N. |
| Abstract Title: | Add-on parsaclisib (a PI3K5 inhibitor) in patients with myelofibrosis and suboptimal response to ruxolitinib: Interim analysis from a phase 2 study |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | myelofibrosis; pi3k; phase 2; ruxolitinib; mpn |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S354 |
| End Page: | S355 |
| Language: | English |
| ACCESSION: | WOS:000691910500257 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01819-x |
| Notes: | Meeting Abstract: MPN-127 -- Source: Wos |
